Skip to main content

Osteoporotic Fractures

0
Pipeline Programs
2
Companies
4
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 3 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Spine BioPharma
Spine BioPharmaNY - New York
3 programs
Percutaneous vertebroplastyN/A1 trial
Posterior stabilizationN/A1 trial
VertebroplastyN/A1 trial
Active Trials
NCT01537770Completed52Est. Apr 2015
NCT07027306Recruiting648Est. Dec 2030
NCT06141187Recruiting240Est. Dec 2030
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
DenosumabN/AMonoclonal Antibody1 trial
Active Trials
NCT05866029Recruiting2,478Est. Sep 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Spine BioPharmaPosterior stabilization
Spine BioPharmaVertebroplasty
UNION therapeuticsDenosumab
Spine BioPharmaPercutaneous vertebroplasty

Clinical Trials (4)

Total enrollment: 3,418 patients across 4 trials

NCT07027306Spine BioPharmaPosterior stabilization

The Osteoporotic Fracture Classification-based Scoring System for Treatment Decision in Thoracolumbar Osteoporotic Fractures

Start: Mar 2026Est. completion: Dec 2030648 patients
N/ARecruiting

Percutaneous Vertebroplasty Vs. Sham for Osteoporotic Vertebral Compression Fractures Focusing on Pain and Economy.

Start: Jan 2024Est. completion: Dec 2030240 patients
N/ARecruiting

Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture

Start: May 2023Est. completion: Sep 20262,478 patients
N/ARecruiting
NCT01537770Spine BioPharmaPercutaneous vertebroplasty

Vertebroplasty Compared With a Sham-procedure for Painful Acute Osteoporotic Vertebral Fractures

Start: Feb 2012Est. completion: Apr 201552 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 actively recruiting trials targeting 3,418 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.